Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus

Atherosclerosis

Volumn 169, Issue 2, 2003, Pages 317-321

  Matsumoto, Kazunari ^a   Sera, Yasunori ^a   Abe, Yasuyo ^a   Ueki, Yukitaka ^a   Tominaga, Tan ^a   Miyake, Seibei ^a  

^a SASEBO CHUO HOSPITAL   (Japan)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Inflammation; Insulin resistance

Indexed keywords

C REACTIVE PROTEIN; RECOMBINANT HUMAN INSULIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG TOLERABILITY; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; JAPAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SMOKING; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 0142061113     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00198-9     Document Type: Article

References (32)

1. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
2. DeFronzo R.A., Ferannini E. Insulin resistance; a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14:1991;173-194.
3. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G., Moorjani S., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334:1996;952-957.
4. Laakso M. How good a marker is insulin revel for insulin resistance? Am. J. Epidemiol. 137:1993;959-965.
5. Matsumoto K., Miyake S., Yano M., Ueki Y., Yamaguchi Y., Akazawa S., et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care. 20:1997;1562-1568.
6. Yip J., Facchini F.S., Reaven G.M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J. Clin. Endocrinol. Metab. 83:1998;2773-2776.
7. Wasada T., Katsumori K., Kuroki H., Iwamoto Y. Insulin resistance facilitates the development of coronary artery disease in Japanese type 2 diabetic patients: a single hospital-based follow-up study. Diabetologia. 42:1999;1264-1265. Letter.
8. Ross R. Atherosclerosis. An inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
9. Libby P.L., Ridker P.M. Novel inflammatory markers of coronary risk. Circulation. 100:1999;1148-1150.
10. Ridker P.M., Cushman M., Stampfer M., Tracy R., Hennekens G.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336:1997;973-979.
11. Ridker P.M., Rifai N., Clearfield M., Downs J., Weis S., Miles J., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344:2001;1959-1965.
12. Rost N.S., Wolf P.A., Kase C.S., Kelly-Hayes M., Silbershatz H., Massaro J., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. Stroke. 32:2001;2575-2579.
13. Jager A., Hinsvergh V.W.M., Kostense P.J., Emeis J.J., Yudkin J.S., Nijpels G., et al. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn study. Arterioscl. Thromb. Vasc. Biol. 19:1999;3071-3078.
14. Stehouwer C.D.A., Gall M., Twisk J.W.R., Knudsen E., Emeis J.J., Parving H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes. 51:2002;1157-1165.
15. World Health Organization. Diabetes mellitus. Report of a WHO study group. Geneva; 1985. (Tech. Rep. Ser., no. 727).
16. Rossetti L., Giaccari A., DeFronzo R.A. Glucose toxicity. Diabetes Care. 13:1990;610-630.
17. Bonora E., Moghetti P., Zancanaro C., Cigolini M., Querena M., Cacciatori V., et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J. Clin. Endocrinol. Me. 68:1989;374-378.
18. Matsumoto K., Yano M., Miyake S., Ueki Y., Yamaguchi Y., Akazawa S., et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 21:1998;256-260.
19. Rifai N., Tracy R., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin. Chem. 45:1999;2136-2141.
20. Matsumoto K., Miyake S., Yano M., Ueki Y., Yamaguchi Y., Akazawa S., et al. Insulin resistance and arteriosclerosis obliterans in patients with NIDDM. Diabetes Care. 20:1997;1738-1743.
21. Matsumoto K., Miyake S., Yano M., Ueki Y., Miyazaki A., Hirao K., et al. Insulin resistance and classic risk factors in type 2 diabetic patients with different subtypes of ischemic stroke. Diabetes Care. 22:1999;1191-1195.
22. Matsumoto K., Sera Y., Abe Y., Ueki Y., Miyake S. Serum concentrations of soluble vascular cell adhesion molecule-1 and E-selectin are elevated in insulin-resistant patients with type 2 diabetes. Diabetes Care. 24:2001;1697-1698. Letter.
23. Welborn T.A., Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentration. Diabetes Care. 2:1979;154-160.
24. Ducimetiere P., Eschwege E., Papoz L., Richard J., Claude J., Rosselin G. Relationship of plasma insulin level to the incidence of myocardial infarction and coronary heart disease mortality in middle-aged population. Diabetologia. 19:1980;205-210.
25. Bergman R.N., Finegood D.T., Ader M. Assessment of insulin sensitivity in vivo. Endocr. Rev. 6:1984;45-86.
26. Yudkin J.S., Stehouwer C.D.A., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 19:1999;972-978.
27. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation. 102:2000;42-47.
28. Paolisso G., Giugliano D. Oxidative stress and insulin action: is there a relationship? Diabetologia. 39:1996;357-363.
29. Cominacini L., Garbin U., Pasini A.F., Campagnola M., Davoli A., Foot E., et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes. 47:1998;130-133.
30. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation. 101:2000;235-238.
31. Suzuki M., Shinozaki K., Kanazawa A., Hara Y., Hattori Y., Tsushima M., et al. Insulin resistance as an independent risk factor for carotid wall thickening. Hypertension. 28:1996;593-598.
32. Folsom A.R., Pankow J.S., Tracy R.P., Arnett D.K., Peacock J.M., Hong Y., et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am. J. Cardiol. 88:2001;112-117.